Status: Recruiting
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
Participants needed: 88
Trial details
Phase: Early Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Kariya PharmaceuticalsUpdated: Mar 7, 2025Locations: 1
Eligibility criteria
Healthy as determined by a responsible physician, based on medical evaluation in... [+1]
Clinically relevant history of abnormal physical or mental health interfering wi... [+1]